We improve
quality of life
by creating new
medicines
News
Scientific review: Favipiravir as a treatment for RNA viruses, including COVID-19
ChemRar Group announces the Russian Avifavir® drug is effective against variants of COVID-19, including Delta and Omicron
Avifavir® for the treatment of COVID-19 is rated among Russia’s TOP 100 Inventions
Leading infectious disease experts in Russia recognized the efficacy of Avifavir®
Avifavir obtains its first registration in Asia
Infrastructure & Facilities
ChemRar Research and Development Institute
Vivarium and biochemical laboratories (GLP)
Chemical Diversity Research Institute
Production of innovative drugs and generics (GMP)
BioIntegrator
Production of biotechnological medicines and vaccines
API-Technology
Production of pharmaceuticals ingredients (GMP)
ChemRar vision & mission
We develop and manufacture effective, safe and affordable medicines for the treatment of socially significant diseases and improvement of the quality of life:
- Using experience and global standards at all stages of creation of a novel medicine;
- Contributing to the development of the scientific and technological potential of the pharmaceutical industry in Russia;
- Applying our knowledge to search for optimal solutions for our partners.
We develop and manufacture effective, safe and affordable medicines for the treatment of socially significant diseases and improvement of the quality of life:
- Using experience and global standards at all stages of creation of a novel medicine;
- Contributing to the development of the scientific and technological potential of the pharmaceutical industry in Russia;
- Applying our knowledge to search for optimal solutions for our partners.
Product pipeline
Avineuro
Avineuro is engaged in research and development of original drugs for the treatment of CNS disorders
Viriom
Viriom company at ChemRar High-Tech Center develops innovative antiviral drugs and combinations, methods of treatment and diagnosis
CardioSystem
Pharma
Pharma
CardioSystemPharma has developed and is launching on the Russian market a new cardioplegic drug, Normacor, for open-heart surgery at a normal body temperature
Aviron
The Aviron project of ChemRar Group implements a program for the development of innovative antiviral drugs with different complementary mechanisms of action for the treatment of chronic hepatitis C, which is included in the list of socially significant diseases and known as “the silent killer”.
NewVac
NewVac is engaged in the research and development of personalized and combination approaches to cancer therapy.
Chromis
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group launched JV Chromis for production of antiviral drug Avifavir based on Favipiravir.
